poisar

Stock

Connect Biopharma Holdings Limited CNTB

$2.55+0.39%

Overview

CNTB market data

Price History

CNTB price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$1.00
Diluted earnings per share over the trailing twelve months.
Beta
-0.19
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-21,243.4%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1.23 – $3.82
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $159.9M · P/B 0.83 · P/S 686.39.

Company News

10 captured
Connect Biopharma Expects Topline Results From Phase 2 Seabreeze STAT Studies In September 2026Benzinga · Aug 12, 2026, 9:16 PM
Connect Biopharma Hldgs Q2 EPS $(0.27) Beats $(0.31) Estimate, Sales $2.768M Beat $650.000K EstimateBenzinga · Aug 12, 2026, 8:25 PM
8-K filing — Connect Biopharma Holdings Ltd (CNTB)SEC EDGAR · Aug 12, 2026, 8:13 PM
Oppenheimer Initiates Coverage On Connect Biopharma Hldgs with Outperform Rating, Announces Price Target of $8Benzinga · Jul 9, 2026, 1:40 PM
Piper Sandler Initiates Coverage On Connect Biopharma Hldgs with Overweight Rating, Announces Price Target of $7Benzinga · Jun 26, 2026, 1:50 PM
HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price TargetBenzinga · Jun 25, 2026, 12:55 PM
Connect Biopharma Completes Enrollment In Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart As Adjunct To Standard Of Care For Acute Exacerbations In Asthma And Type 2 InflammationBenzinga · Jun 17, 2026, 1:10 PM
This Lear Analyst Turns Bullish; Here Are Top 4 Upgrades For TuesdayBenzinga · May 26, 2026, 4:12 PM
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For TuesdayBenzinga · May 26, 2026, 12:56 PM
Canaccord Genuity Initiates Coverage On Connect Biopharma Hldgs with Buy Rating, Announces Price Target of $6Benzinga · May 26, 2026, 12:32 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock